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ABSTRACT
Objective: To assess the utility and safety of rituximab in pediatric autoimmune and inflammatory
disorders of the CNS.
Methods: Multicenter retrospective study.
Results: A total of 144 children and adolescents (median age 8 years, range 0.7–17; 103 female)
with NMDA receptor (NMDAR) encephalitis (n 5 39), opsoclonus myoclonus ataxia syndrome (n 5
32), neuromyelitis optica spectrum disorders (n 5 20), neuropsychiatric systemic lupus erythema-
tosus (n 5 18), and other neuroinflammatory disorders (n 5 35) were studied. Rituximab was given
after amedian duration of disease of 0.5 years (range0.05–9.5 years). Infusion adverse eventswere
recorded in 18/144 (12.5%), including grade 4 (anaphylaxis) in 3. Eleven patients (7.6%) had an
infectious adverse event (AE), including 2 with grade 5 (death) and 2 with grade 4 (disabling) infec-
tious AE (median follow-up of 1.65 years [range 0.1–8.5]). No patients developed progressive mul-
tifocal leukoencephalopathy. A definite, probable, or possible benefit was reported in 125 of 144
(87%) patients. A total of 17.4% of patients had a modified Rankin Scale (mRS) score of 0–2 at
rituximab initiation, compared to 73.9%at outcome. The change inmRS0–2was greater in patients
given rituximab early in their disease course compared to those treated later.
Conclusion: While limited by the retrospective nature of this analysis, our data support an off-
label use of rituximab, although the significant risk of infectious complications suggests rituximab
should be restricted to disorders with significant morbidity and mortality.
Classification of evidence: This study provides Class IV evidence that in pediatric autoimmune and
inflammatory CNS disorders, rituximab improves neurologic outcomes with a 7.6% risk of
adverse infections. Neurology® 2014;83:142–150
GLOSSARY
AE5 adverse events; CMV5 cytomegalovirus; CTCAE5Common Terminology Criteria for Adverse Events; DoD5 duration
of disease;mRS5modified Rankin Scale; NMDAR5NMDA receptor; NMO5 neuromyelitis optica; NMOSD5 neuromyelitis
optica spectrum disorders; OMAS 5 opsoclonus myoclonus ataxia syndrome; PML 5 progressive multifocal
leukoencephalopathy.
Rituximab is an anti-CD20 chimeric monoclonal antibody that results in B-cell depletion. Ini-
tially used to treat B-cell neoplasms such as non-Hodgkin lymphoma,1 rituximab has more
recently been licensed for use in autoimmune disorders such as rheumatoid arthritis and anti-
neutrophil cytoplasmic antibody–associated vasculitides.2,3 In a double-blind placebo-controlled
trial, rituximab reduced disease activity in relapsing-remitting multiple sclerosis,4 and open-label
studies have described benefit in NMDA receptor (NMDAR) encephalitis, neuromyelitis optica
(NMO) spectrum disorders (NMOSD), and opsoclonus myoclonus ataxia syndrome (OMAS).5–7
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New biologic therapies such as rituximab have
provided clinical benefits, but concerns about
safety remain, particularly regarding serious
infection and viral reactivation.8,9 Rituximab
usage in children has increased over the last
10 years for a broad spectrum of indications
including post-transplant complications, malig-
nancy, immunodeficiency, and autoimmune
disease.8 Serious infection in children following
rituximab is more common for transplant and
malignancy indications than autoimmune indi-
cations, although long-term safety data and for-
mal clinical trials are lacking.8 In order to
improve knowledge regarding the risk/benefit
ratio of rituximab usage, we conducted a retro-
spective multicenter review of the utility and
safety of rituximab in children with autoim-
mune and inflammatory CNS conditions.
METHODS Standard protocol approval and registration.
The study gained new ethical approval or used preexisting eth-
ically approved studies to collect de-identified clinical data from
children who received rituximab using a designed pro forma
(QIE-2013-02-17).
Cohort data collection. The primary research aim was to
define the utility and safety of rituximab in a retrospective cohort
study (Class IV evidence). Using a network of 15 pediatric inter-
national centers with an interest in neuroimmunology, our pri-
mary aims were to survey the use, safety, and efficacy of rituximab.
We collected data from patients treated for autoimmune or inflam-
matory CNS indications prior to their 18th birthday. Patients were
captured using combinations of electronic medical records, clinical
databases, or pharmacy records. The data were collected and
rated by one primary investigator per site, with cross-checking
with attending clinicians and coinvestigators.
The designed pro forma (appendix e-1 on the Neurology® Web
site at Neurology.org) collected demographic data, age at presenta-
tion, age at rituximab administration, the dosage regimen used, and
medication to reduce allergic phenomena. The clinical syndrome,
diagnosis, and diagnostic investigations were recorded, as were im-
munotherapies that were used before rituximab or at any time
during the patient’s illness. Hematologic and immunologic analyses
were based upon available laboratory tests that were ordered for
clinical purposes. The presence of hematologic effects was recorded
as previously described.10 B-cell depletion was assessed using CD19
count, and we also recorded whether the B-cell depletion was pre-
sent .12 months after rituximab. Infusion adverse events (AEs)
were symptoms or signs that occurred during the infusion that were
considered allergic, hypersensitive, or other unwanted effects of the
infusion. The management of the side effects was not recorded.
Infusion AEs were recorded as described on product data sheets and
classified using Common Terminology Criteria for Adverse Events
(CTCAE v4.0), as has been previously used in this context.10–12We
recorded any side effect that may have been attributed to rituximab
usage, with particular focus on infectious complications, which
were classified using CTCAE v4.0.11 The development of progress-
ive multifocal leukoencephalopathy (PML) was specifically queried.
While therapeutic efficacy could not be formally evaluated in
a retrospective analysis, we evaluated the clinical disease state at
initiation and following rituximab using the modified Rankin
Scale (mRS) for children.6,13 The mRS was recorded for the
“worst at any stage,” at initiation of rituximab, and at outcome.
An mRS of 0–2 was used as a marker of a better outcome, as
previously described.6 We also subjectively classified response to
rituximab, as recorded by the attending clinician as “definite
improvement,” “probable improvement,” “possible improve-
ment,” “no benefit,” or “disease worsening during therapy.”
The duration of disease (DoD) at the time of rituximab admin-
istration was calculated, and the median DoD for each of the
main subgroups was calculated (NMDAR encephalitis, OMAS,
NMOSD, and neuropsychiatric systemic lupus erythematosus).
In order to determine the change in mRS related to the timing of
rituximab therapy, we divided patients according to the median
DoD at the time of rituximab initiation into early (# median)
and late (. median) in the 4 main subgroups. The duration of
follow-up and ongoing disability at the last documented visit was
recorded. Therapies being received at last clinic follow-up were
also recorded. Figures were generated using Prism software ver-
sion 4.0b (GraphPad Software, Inc., San Diego, CA).
RESULTS Clinical cohort and subgroup demographics.
Data from 144 patients (103 female) were available.
The age at first neurologic presentation was a median
of 8 years (range 0.7–17 years). The disease subgroups
are presented in table 1. There was a total duration
of follow-up of 307 patient-years after rituximab
administration (median 1.65 years, range 0.1–8.5
years). A total of 134 of 144 patients were followed
for longer than 6 months.
Preceding or concurrent therapies. Most patients had
a prolonged or relapsing course requiring multiple
immunosuppressive or immune-modifying therapies.
At some point prior to the first rituximab infusion,
138 patients were treated with one or more doses of
corticosteroids, 104 received one or more courses of
IV immunoglobulin, 43 were treated with a single
or multiple dose regimen of cyclophosphamide, and
21 underwent plasma exchange (as summarized in
table e-1).
Rituximab administration. The age at rituximab adminis-
tration was a median of 9.9 years (range 1.6–17.9 years).
The duration of disease before rituximab usage was a
median of 0.5 years (range 0.05–9.5 years), and varied
by disease (table 2). At the time of rituximab initiation,
the medianmRS was 3 (range 0–5). A variety of dosage
regimens were employed as outlined in table e-2, with
375 mg/m2 weekly for 4 weeks being the most com-
monly used regimen (n 5 57). Antihistamine was
administered with the infusion in 106 patients. A total
of 112 patients received corticosteroid with the infu-
sion or were receiving ongoing corticosteroid at the
time of rituximab. Twenty-six patients were
commenced on ongoing prophylactic antibiotic
(usually cotrimoxazole); 15 of these patients also
received cyclophosphamide during their disease.
Monitoring for potential viral reactivation syndromes
described after rituximab10 was inconsistent: viral
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serology was performed for JC virus (n5 14), varicella-
zoster virus (n5 14), hepatitis B and C (n5 13), and
BK virus (n 5 3). Thirty-eight patients had repeat
rituximab courses, with patients with NMO most
likely to receive repeat courses (table 2). The timing
of the repeat courses was not reported.
Hematologic and immunologic effects. Measurement of
hematologic and immunologic effects was recorded in
124 of 144 patients after rituximab (there was inade-
quate data in 20 patients). Complete blood count and
differential, lymphocyte subsets (B-cell count), and
immunoglobulin were performed, and results are pre-
sented in table 3. A total of 119 of 124 (96%) had
B-cell depletion (actual values not recorded), which
was present.12 months in 12 children, and 27 chil-
dren had documented hypogammaglobulinemia
(table 3). Other hematologic effects were uncommon,
including neutropenia.
Infusion AEs.Of 144 patients, 18 patients (12.5%) had
one or more infusion-related symptoms (table 4). The
timing of the infusion side effects (e.g., first infusion,
second infusion) was not recorded. Three patients
(2%) had a grade 4 reaction (anaphylaxis) that
resolved without complication with standard therapy
including antihistamine and corticosteroid doses.
One of these children did not receive antihistamine
prophylaxis. In one patient, infusion-related fever
created a transient exacerbation of seizures. Only one
patient was unable to tolerate rituximab due to
progressively worse hypersensitivity reactions despite
premedication and hence was suspended after the
fourth incomplete dose. This patient, with NMOSD,
subsequently tolerated and completed a course of
ofatumumab. There was no difference in infusion AEs
between those who received antihistamine prophylaxis
(13/106, 12%), and those who did not (5/38, 13%).
Infectious side effects. Eleven patients (7.6%) had a re-
corded infectious complication in the follow-up period
(table 4). Two children had a grade 5 (death) AE, and
2 children a grade 4 (life-threatening or disabling) AE
(table 4, and described in appendix e-2).14 The grade
4 and 5 infectious AEs occurred a median of 30 days
(range 3–38 days) after initiation of rituximab. A further
7 patients had a grade 3 infectious AE (hospitalization or
IV antibiotics) in the follow-up period that may have
been partly related to rituximab immunosuppression
(table 4). An infectious AE occurred in 2 of the
26 patients on antibiotic prophylaxis (7.7%),
compared to 9 of 118 patients not on prophylaxis
(7.6%). An infectious AE occurred in 2 of 58 patients
(3.4%) who received cyclophosphamide at any stage
during their disease, compared to 9 of 86 (7.6%) who
did not receive cyclophosphamide. There were no cases
Table 1 Autoimmune or inflammatory CNS disorders treated with rituximab in descending order of frequency
Disease No. Female
Age at presentation, y,
median (range) Diagnostic marker
NMDAR encephalitis 39 29 8.7 (1.6–17) CSF NMDAR Ab (n 5 34), serum NMDAR Ab (n 5 5), ovarian
teratoma (n 5 3)
Opsoclonus myoclonus ataxia syndrome 32 20 1.8 (0.7–8.25) Clinical syndrome only (n 5 21), neural crest tumor (n 5 11)
Neuromyelitis optica spectrum disorders 20 14 10.5 (2–16.8) NMO IgG– or AQP4 IgG–positive (n 5 18)
NPSLEa 18 17 13.0 (8–17) Lupus antibodies (n 5 18), APS antibodies (n 5 6)
Cerebral vasculitis 6 5 7.5 (4–9.4) Pathology (n 5 3), pANCA (n 5 2)
VGKC encephalitis 6 5 10.5 (1.5–15) Positive serum VGKC-complex Ab (n 5 6)
Other suspected autoimmune encephalitis 5 2 8 (5–13.5) NMDAR encephalitis–like (negative CSF NMDAR Ab) (n 5 3), LE (n 5 3)
Multiple sclerosis 4 3 9.1 (3.5–16.9) MRI (n 5 4), intrathecal OCB (n 5 2), biopsy (n 5 2)
Rasmussen encephalitis 4 2 6.2 (5.7–8) MRI (n 5 4)
GAD Ab-associated encephalitis 2 1 15.6 (15.2–16) High titer serum GAD Ab (n 5 2), CSF GAD Ab (n 5 1), MRI LE (n 5 1)
Autoimmune thyroid-associated encephalitis
(TPO Ab)
2 2 10.6 (10.3–11) TPO antibody–positive (n 5 2), MRI LE (n 5 1)
Febrile infection–related epilepsy syndrome 2 0 6 (5–7) Clinical syndrome (n 5 2)
Autoimmune CNS and PNS demyelinating
disease
2 2 9.8 (5–14.6) MRI (n 5 2), NCS (n 5 2)
Otherb 2 1 6.9 (4–9.8) MRI (n 5 1), EBV PCR (n 5 1)
Abbreviations: Ab 5 antibody; APS 5 antiphospholipid syndrome; EBV 5 Epstein-Barr virus; GAD 5 glutamic acid decarboxylase; IgG 5 immunoglobulin G;
LE 5 limbic encephalitis; NCS 5 nerve conduction studies; NMDAR 5 NMDA receptor; NMO 5 neuromyelitis optica; NPSLE 5 neuropsychiatric systemic
lupus erythematosus; OCB 5 oligoclonal bands; pANCA 5 perinuclear antineutrophil cytoplasmic antibodies; PNS 5 peripheral nervous system; TPO 5
thyroid peroxidase; VGKC 5 voltage-gated potassium channel complex–antibody associated.
a Six of the 18 patients with NPSLE had coexistent APS. Four of the patients with NPSLE had myelitis as part of the CNS syndrome.
bCNS complications of autoimmune pancytopenia (n 5 1), EBV leukoencephalopathy in hyper immunoglobulin E syndrome (n 5 1).
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Table 2 Rituximab treatment in each subgroup according to timing of administration, length of follow-up, benefit, modified Rankin Scale scores, and continuing therapy
Disease (n) Preceding immunotherapies
Disease duration
before RTX, y,
median (range)
Benefit: Definite, probable,
possible, none, worsening
Median Rankin
Scale score:
Worst, at RTX
administration,
outcome
Duration of
follow-up post
RTX, median
(range)
Ongoing
disability
or death Ongoing treatments at last clinic visit
NMDAR encephalitis (39) Steroid (n 5 37); IVIg (n 5 34); PE
(n 5 11); Cyclo (n 5 8); MMF or
azathioprine (n 5 4)
0.1 (0.05–5.1) 16 definite, 16 probable,
6 possible, 1 none
5, 4, 1 1.3 (0.4–4.5) 32/39 (2
deaths)
Rituximab (n 5 10); steroid (n 5 4); IVIg
(n 5 6); MMF (n 5 1)
OMAS (32) Steroid (n 5 30); IVIg (n 5 30); Cyclo
(n 5 10); azathioprine (n 5 1)
1.1 (0.05–6.8) 11 definite, 13 probable,
7 possible, 1 none
4, 3, 2 2.5 (0.1–8.5) 22/32 Rituximab (n 5 6); steroid (n 5 8); IVIg
(n 5 14); MMF (n 5 1)
NMO (20) Steroid (n 5 20); IVIg (n 5 9); MMF or
azathioprine (n 5 8); Cyclo (n 5 6); PE
(n 5 2)
0.78 (0.05–10.5) 7 definite, 6 probable,
6 possible, 1 none
4, 2.5, 1 2.0 (0.4–5) 13/20 Rituximab (n5 12); MMF or azathioprine
(n 5 4); steroids (n 5 2)
NPSLE (18) Steroid (n 5 17); IVIg (n 5 9); Cyclo
(n 5 9); PE (n 5 4); MMF/azathioprine
(n 5 4); hydroxychloroquine (n 5 4)
0.2 (0.05–6) 5 definite, 7 probable,
5 possible, 1 none
4, 3, 1 1.7 (0.3–10) 12/18 Rituximab (n 5 3); MMF or azathioprine
(n 5 14); Cyclo (n 5 2);
hydroxychloroquine (n 5 6)
Cerebral vasculitis (6) Steroid (n 5 6); IVIg (n 5 1); Cyclo
(n 5 6); MMF, azathioprine, Mtx
(n 5 5); infliximab (n 5 2)
1.7 (0.5–3.25) 1 definite, 3 probable,
0 possible, 1 none,
1 worsening
3, 2, 1.5 2.5 (0.4–4) 4/6 Rituximab (n 5 1); MMF or azathioprine
(n 5 3); abatacept (n 5 1); infliximab
(n 5 1)
VGKC encephalitis (6) Steroid (n 5 6); IVIg (n 5 6); Cyclo
(n 5 3); PE (n 5 2)
0.7 (0.1–1) 1 definite, 2 probable,
1 possible, 2 none
5, 3.5, 2 0.9 (0.3–2) 5/6 Rituximab (n 5 2); steroid (n 5 2); IVIg
(n 5 1)
Suspected autoimmune
encephalitis (5)
Steroid (n 5 5); IVIg (n 5 5) 0.1 (0.1–1) 1 definite, 1 probable,
1 possible, 2 none
5, 5, 3 1 (0.4–3) 4/5 Rituximab (n 5 1); steroid (n 5 2); IVIg
(n 5 2)
Multiple sclerosis (4) Steroid (n 5 4); IVIg (n 5 2); Cyclo
(n5 2); b-interferon (n5 3); glatiramer
(n 5 2); natalizumab (n 5 1)
5.4 (3–9.5) 1 definite, 0 probable,
1 possible, 1 none,
1 worsening
4, 3.5, 2 3.3 (1.8–4.5) 4/4 Azathioprine (n 5 1); fingolimod (n 5 1);
Cyclo (n 5 1); IVIg (n 5 1); Cyclo (n 5 1)
Rasmussen encephalitis (4) Steroid (n 5 4); IVIg (n 5 4); plasma
exchange (n 5 1); azathioprine (n 5 1)
3.2 (0.05–6.6) 1 definite, 0 probable,
0 possible, 3 none
4, 3.5, 3 2.5 (2–5.3) 4/4 Rituximab (n 5 1); hemispherectomy
(n 5 2); azathioprine (n 5 1)
Abbreviations: Cyclo 5 cyclophosphamide; IVIg 5 IV immunoglobulin; Mtx 5 methotrexate; MMF 5 mycophenolate mofetil; NMDAR 5 NNMDA receptor; NMO 5 neuromyelitis optica; NPSLE 5 neuropsychiatric
systemic lupus erythematosus; OMAS 5 opsoclonus myoclonus ataxia syndrome; PE 5 plasma exchange; RTX 5 rituximab; VGKC 5 voltage-gated potassium channel.
Subgroups over n 5 4 are included.
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of PML, nor any secondary malignancy identified
during the reporting period (total 307 patient-years of
follow-up).
Young patients. We compared the safety data in pre-
school children#5 years old (n5 46) with the children
.5 years of age. There was no difference in hematologic
or immunologic effects, except an increased rate of hypo-
gammaglobulinemia (table 3). In the children#5 years,
there was no increased risk of infusion AEs (7/46, 15%
vs 11/98, 11%) and no increased risk of infectious
AE (3/46, 6.5% vs 8/98, 8%) compared to the children
.5 years. Two of the 3 children #5 years with infec-
tious AE had persistent hypogammaglobulinemia.
Outcome of cohort. A total of 35 of 144 (24%) pa-
tients required intensive care management. After a
median follow-up of 1.65 years after rituximab
(range 0.1–8.5), 3 patients (2%) died. Two patients
who died had NMDAR encephalitis, as described in
the supplementary material. The third patient who
died had GAD antibody–associated encephalitis and
died 3 months into the illness due to refractory status
epilepticus. A total of 101 patients (70%) had residual
problems including cognitive or developmental
impairment (n 5 66), motor impairment (n 5 46),
psychiatric disease (n 5 34), or visual impairment
(n 5 13). Sixteen children continue to experience
seizures. Forty children (28%) experienced a full
clinical recovery at the end of the observation period.
According to the impression of the treating clini-
cian, rituximab had a definite benefit in 45 patients,
probable benefit in 49, possible benefit in 31, no ben-
efit or unclear in 17, and the disease worsened in
2 patients. The median mRS in the total cohort was
4 (worst score), 3 (at rituximab administration), and
2 (at outcome determination). The mRS at initiation
of rituximab and outcome separated by etiology is
presented in table 2. The percentage of patients with
mRS of 0–2 was variable between subgroups, but
showed a general improvement in the main indica-
tions (figure, A). The change in mRS 0–2 was compared
according to the timing of rituximab administration
(early or late, separated according to the median dura-
tion of disease at the time of rituximab initiation). For
the 4 main indications, the change in mRS 0–2 and the
change in median mRS was greater in the “early” groups
compared to the “late” groups (figure, B, and table e-3).
DISCUSSION We describe the clinical features,
treatment protocols, laboratory features, and clinical
outcome of 144 children and adolescents treated with
the CD20 monoclonal antibody rituximab. To date,
unlike in adults,4,15 there are no randomized clinical
trials of any immunotherapy in pediatric CNS
inflammatory disease, leading to off-label use in
severely ill children. While retrospective analysis
of treatment efficacy and safety has methodologic
limitations, it is a critical first step toward enhanced
Table 3 Hematologic and immunologic effects of rituximab
Hematologic or immunologic
effect
All patients (124
of 144), n (%)
Patients £5 y (39
of 46), n (%)
Patients >5 y (85
of 98), n (%)
Lymphopenia 51 (41) 17 (44) 34 (40)
Lymphopenia >12 mo 8a (6) 2 (5) 6 (7)
B-cell depletion 119 (96) 35 (90) 84 (99)
B-cell depletion >12 mo 12 (10) 6 (15) 6 (7)
Hypogammaglobulinemia 27 (22) 11 (28) 16 (19)
Immunoglobulin G
hypogammaglobulinemia
23 7 16
Immunoglobulin M
hypogammaglobulinemia
4 2 2
Immunoglobulin A
hypogammaglobulinemia
2 2 0
Anemia 1 1 0
Thrombocytopenia 2 1 1
Neutropenia 1 0 1
Pancytopenia 0 0 0
The data from children #5 years old at rituximab administration are also presented (of
46 patients, there was adequate information in 39). There was adequate information in
124 of 144 patients.
a Seven of 8 with persistent lymphopenia had additional cyclophosphamide.
Table 4 Infusion and infectious adverse events in 144 patients
Adverse events Category Number (%) Details
Infusion Any 18 (12.5)
Grade 4 3 (2) Anaphylaxis
Grade #3 15 (10) Skin rash (n 5 6), fever (n 5 4), flu-like (n 5 2), tachycardia (n 5 2), chest pain (n 5 2), headache,
bradycardia, hypotension, hypertension, panic attack, trembling sensation, facial swelling, and exacerbation
of tremor (all n 5 1)
Infectious AE Any 11 (7.6)
Grade 5 (death) 2 (1.4) Cytomegalovirus colitis (complicated by fatal bowel perforation); staphylococcal toxic shock syndrome
Grade 4 (disabling) 2 (1.4) Cytomegalovirus retinitis; shock and hypoxic brain injury
Grade 3 7 (5) Pneumonia (n 5 2), empyema, bronchiectasis, salmonella enteritis, Clostridium difficile enteritis, mastoiditis
(all n 5 1)
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appreciation of the role of such therapies in child and
adolescent patient populations.
Rituximab was administered after a median of
0.5 years of disease, indicating that rituximab is gener-
ally given as a second-line immunosuppressant, typi-
cally after corticosteroids. Rituximab was also given
for relapse prevention and to allow corticosteroid
reduction. Despite an apparent benefit in many pa-
tients, after a median follow-up of 1.65 years after rit-
uximab treatment, there was mortality of 2% and
ongoing morbidity of 70%, indicating that this cohort
of patients had severe and often refractory disease.
The variable dosing regimen utilized across the
different pediatric centers reflects the different dosage
regimens for differing indications in adult medicine.10
A recent report has shown that significantly lower
doses of rituximab (100 mg weekly for 3 weeks) can
produce effective B-cell depletion in Chinese adults
with NMO,16 although lower doses may not result in
improved safety profiles. A standardized infusion pro-
cess was not consistent between sites. Antihistamines
and concomitant corticosteroids are recommended to
reduce the incidence of infusion-related side effects.10
Given the infusion reactions experienced by the
Figure Modified Rankin Scale score at initiation of rituximab and at outcome
Modified Rankin Scale (mRS) score compared in all patients (total) and subgroups. (A) Groups are as follows (all patients n5 144 [total]): NMDAR encephalitis
(NMDAR), opsoclonus myoclonus ataxia syndrome (OMAS), neuromyelitis optica spectrum disorders (NMOSD), neuropsychiatric systemic lupus erythema-
tosus (NPSLE), and other groups (others). The follow-up was too short to create a mRS in 2 patients (one with OMAS, one other). mRS 0–2 infers a better
outcome and is presented for each group as a percentage. The dotted line represents the change in mRS 0–2 between rituximab initiation and outcome. (B)
mRS at rituximab initiation and outcome is compared according to the timing of rituximab administration. For each group, we separated an early and late
group using the median duration of disease at rituximab initiation. Details of the timing, the median mRS, and the difference (D) in median mRS between
initiation and outcome are also presented in table e-3.
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children reported (18/144), treating clinicians need to
be alert for allergic complications. We could not doc-
ument a difference in infusion reactions between
those children provided antihistamine treatment con-
comitantly with rituximab, but this does not negate
the potential value of such preventative strategies.
B-cell depletion was induced in 119/124 (96% of
patients who had lymphocyte subset measurement).
Rituximab is often detectable in blood for up to
4 months after administration, and B cells typically
start to return in the peripheral circulation after
6 months, and by 12 months in the majority of pa-
tients.9,17 B-cell depletion beyond 12 months was only
observed in 12 patients, although this may be an
underestimate as serial measurement was not routinely
performed.
The rationale for repeat rituximab dosing is based
on clinical diagnosis and the perceived risk of new at-
tacks. For example, patients with NMO who are
NMO immunoglobulin G (IgG)–positive are prone
to a relapsing course and accrue disability with relap-
ses.18 Understanding the timing of B-cell repopulation
is one way of determining the timing of subsequent
doses. An alternative approach increasingly employed
in autoimmune disease is to administer regular ritux-
imab every 6 months irrespective of B-cell counts to
maintain remission of autoimmune disease. Reduc-
tions in immunoglobulin M (IgM), immunoglobulin
A, or IgG were reported in 27/124 patients, although
immunoglobulin measurements were not routinely
performed prior to the initial rituximab dose and
could have been preexisting in some patients. IgG
or IgM hypogammaglobulinemia is more common
when repeated courses of rituximab are given,19 or
when given with cyclophosphamide.20 Other hema-
tologic effects were uncommon (table 3).
The primary aim of the study was to define the
potential infectious side effects of rituximab in this
pediatric population. There were multiple confound-
ers with this analysis. The patients were often sick,
with 24% requiring intensive care admission, and
the majority of patients received corticosteroids and
other immunotherapies. In total, 11/144 (7.6%)
of the cohort had an infectious (or suspected infec-
tious) AE, although it is probable there were other
more minor infectious illness not reported. Although
some of the infectious complications could have been
multifactorial in etiology, 4 patients had grade 4 or
5 AEs. Two of these patients had symptomatic cyto-
megalovirus (CMV) infection while immunosup-
pressed from rituximab, one of whom had also
received cyclophosphamide. Although B-cell deple-
tion would not typically be considered a risk factor
for viral infection, reactivation of CMV, hepatitis B,
varicella-zoster, herpes simplex, and CNS infection
with enterovirus are recognized AEs with rituximab,10,21
particularly in patients treated for organ transplantation
and malignant indications.8 These viral reactivation
syndromes possibly represent some of the secondary
effects of B-cell depletion on T-cell function.22,23 Rit-
uximab should therefore be considered a broad-acting
immunosuppressive agent. No cases of PML were re-
ported in a total of 307 patient-years of follow-up,
although the numbers are too small and follow-up
too short to determine PML risk in children with
CNS disease. PML was reported in only 1 of 2,875
children treated with rituximab for a broad range of
indications in an International Classification of Diseases
coding survey.8,24 There were a further 7 patients who
had grade 3 AEs (respiratory and gastrointestinal infec-
tions) that were treated without complication. It is con-
ceivable that some of these infections were related to the
acuity and severity of the neurologic disease, rather than
immunosuppression alone.
There was no apparent reduction in serious infec-
tion in the small proportion of patients who received
antibiotic prophylaxis. Antibiotic prophylaxis could
be considered in “higher-risk” patients with preexisting
hypogammaglobulinemia, receiving cyclophosphamide,
with known respiratory disease, or with documented
significant hypogammaglobulinemia after rituxi-
mab, although the complications of chronic antibi-
otic usage should also be considered.
In this cohort, there were 46 children under 5 years
of age at the time of rituximab administration, and
there was no apparent increase in side effects in
these young patients apart from a possible increase
in hypogammaglobulinemia.
The apparent benefit of therapy was recorded in
this cohort, although we acknowledge the following
limitations. First, assessment of benefit was unblinded,
retrospective, and subjective. Secondly, the follow-up
after rituximab was relatively short (median 1.65 years)
and variable between subgroups, and thus long-term
benefits, or risks, remain to be defined. Third, most pa-
tients received other immunotherapies before and after
rituximab; thus ascribing therapeutic benefit and risk
to a single agent is inaccurate. Fourth, assessing efficacy
is difficult in heterogeneous disorders using crude
markers of disability such as the mRS. The outcome
data in this cohort must also be considered in the con-
text of the natural history of these serious disorders. For
example, NMDAR encephalitis in adults and children
has a mortality of 5%,6 and more than 50% of adult
patients with relapsing NMO are blind in one or
both eyes or require ambulatory help within 5 years
of onset.6,18 A further confounder is the fact that some
patients can improve independent of immunosuppres-
sion. The timing of rituximab varied according to eti-
ology as described in table 2, with relatively earlier
usage in autoimmune encephalitis and during the
relapsing or chronic phases in other indications. With
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improved understanding of the risk/benefit ratio, it is
expected that rituximab will be administered earlier in
the disease course when its benefits could be maxi-
mized, as has been recently proposed in opsoclonus
myoclonus ataxia syndrome,25 and as suggested in this
cohort (figure, B). Although subjective, treating clini-
cians often considered rituximab to be beneficial, and
only 2 patients had a disease “worsening,” which is
occasionally observed after rituximab treatment, and
may be secondary to a loss of T-cell regulation.23
Further work to optimize dosing regimens, stan-
dardize laboratory and safety monitoring, and con-
sider patient registries would greatly enhance the
ability to counsel patients and families on the risks
and benefits of rituximab treatment. Formal clinical
trials will be limited by the rarity of each individual
CNS inflammatory disease, and by the need to con-
sider other therapeutic options in these severely ill
patients.
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